NasdaqCM:RGCPharmaceuticals
Regencell Bioscience (RGC) Launches US$500 Million ATM Plan Is Its Funding Strategy Shifting?
In late March 2026, Regencell Bioscience Holdings filed a shelf registration and announced an at-the-market follow-on equity offering of up to US$500 million in common stock.
This move signals that the company is building flexibility to raise substantial capital over time, potentially reshaping its funding mix and balance sheet.
We will now examine how this sizeable at-the-market equity program may influence Regencell Bioscience Holdings’ investment narrative and risk profile.
The latest...